Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed (2024 - 2025)

Silence Therapeutics' Return on Capital Employed history spans 2 years, with the latest figure at 0.66% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 37.0% year-over-year to 0.66%; the TTM value through Dec 2025 reached 0.66%, down 37.0%, while the annual FY2025 figure was 0.44%, 48.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.66% at Silence Therapeutics, down from 0.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.29% in Q4 2024 and bottomed at 0.66% in Q4 2025.